Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Pressemeddelelse

BioStock: Spago Nanomedical's CDO on study submission

Spago Nanomedical

Spago Nanomedical recently submitted the application to start the phase I/IIa study with Tumorad in Australia. Spago's Chief Development Officer Paul Hargreaves visited BioStock's studio to talk about the new radionuclide therapy and the upcoming study.

Watch the interview with Spago Nanomedical's CDO Paul Hargreaves at biostock.se:

https://www.biostock.se/en/2023/05/spago-nanomedicals-cdo-on-study-submission/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.